Tumor News and Research

RSS

Taconic and Oncodesign announce agreement to co-promote and co-develop solutions to advance oncology research

Taconic, a leading provider of life sciences solutions, and Oncodesign(R), an innovative leader in the discovery of novel anti-cancer therapies, announce today that they have entered into an agreement to co-develop and co-promote pre-clinical oncology in vivo solutions for researchers worldwide. The agreement provides researchers with improved access to a large, diverse portfolio of translational models for use in pre-clinical oncology studies, along with supporting scientific services.

24 Oct 2011

Top-line results from Exelixis' cabozantinib phase 3 trial on medullary thyroid cancer

Exelixis, Inc. today reported top-line results from the ongoing phase 3 clinical trial of cabozantinib in patients with advanced medullary thyroid cancer (MTC), known as the EXAM trial.

24 Oct 2011

Mirna, Silence enter agreement to assess delivery systems for novel microRNAs

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, today announced that it has entered into an agreement with Mirna Therapeutics Inc., a biopharmaceutical company pioneering microRNA-based therapeutics for cancer, to assess the delivery capabilities of Silence's proprietary AtuPLEX and DBTC delivery systems for Mirna's novel microRNAs.

24 Oct 2011

Detroit has one of the highest NSCLC mortality rates in the U.S.

Compared with other cities, Detroit has one of the highest mortality rates in the United States for non-small cell lung cancer.

24 Oct 2011

HCI researchers discover new way to model human breast cancer

Researchers from Huntsman Cancer Institute (HCI) at the University of Utah have discovered a new way to model human breast cancer that could lead to new tools for predicting which breast cancers will spread and new ways to test drugs that may stop its spread.

24 Oct 2011

Old age not synonymous with impairment and disability

Exceptional cognitive and physical function in old age leaves a tell-tale immunologic fingerprint, say researchers at the University of Pittsburgh and Children's Hospital of Pittsburgh of UPMC. Likewise, older adults who have mild impairments bear a distinct immunologic pattern, too, according to findings published today in the Public Library of Science: One.

22 Oct 2011

New mathematical models can predict prostate cancer aggressiveness

Alexander R. A. Anderson, Ph.D., co-director of Integrative Mathematical Oncology (IMO) at Moffitt Cancer Center, and his colleagues, Simon Hayward, Ph.D., at Vanderbilt University and Gustavo Ayala, M.D., at Baylor College of Medicine, have received a five-year, $3 million grant from the National Institutes of Health to create new mathematical models to predict prostate cancer aggressiveness.

22 Oct 2011

Two proteins bind together to ignite and sustain malignant brain tumors

Two previously unassociated proteins known to be overly active in a variety of cancers bind together to ignite and sustain malignant brain tumors, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports this week in the journal Cancer Cell.

22 Oct 2011

Loyola surgical oncologist removes high-grade liver tumor

The cancerous tumor in Marcus Muhich's liver weighed 8 pounds and was nearly a foot across. Doctors at three major academic medical centers in the Midwest told Muhich his high-grade tumor was inoperable.

22 Oct 2011

Two Philadelphia scientists to receive John Scott Award

Two internationally recognized scientists with strong Philadelphia ties are to receive the John Scott Award this year.

21 Oct 2011

Weill Cornell researcher to study link between obesity, inflammation and breast cancer

Funded through Bloomingdale's annual Pink Campaign, The Breast Cancer Research Foundation (BCRF) is awarding a grant to Dr. Andrew J. Dannenberg of Weill Cornell Medical College on Oct. 26 to fund research into the link between obesity, inflammation and breast cancer. Dr. Dannenberg has been a BCRF grantee since 2004.

21 Oct 2011

UH scientists recommend new drug strategies for chronic diseases

Researchers at the University of Houston (UH) are recommending a new strategy for developing drugs to treat cancer, multiple sclerosis, Alzheimer's and cardiovascular diseases.

21 Oct 2011

Dual role for VEGF in regulating skin cancer stem cells and tumor progression

In a study published in Nature, researchers lead by Cédric Blanpain, MD/PhD, FNRS/FRS researcher and WELBIO investigator at the IRIBHM, Université libre de Bruxelles, Belgium, in collaboration with the groups of Peter Carmeliet (VIB/K.U.Leuven) and Jody J. Haigh (VIB/UGent) identify a new role for Vascular Endothelial Growth Factor (VEGF) in regulating skin cancer stem cells.

21 Oct 2011

OncoGenex commences enrollment in OGX-427 Phase II trial for bladder cancer

OncoGenex Pharmaceuticals, Inc. announced today that it has initiated patient enrollment in a randomized, Phase II clinical trial evaluating OGX-427, an inhibitor of heat shock protein 27 (Hsp27), in patients with advanced bladder cancer.

21 Oct 2011

Pap test the best for cervical cancer screening

The Pap test - a lab exam of cells scraped from the cervix, the gateway to the uterus - is an effective way to screen young and middle-aged women - and it's only needed once every three years, say scientists advising the government.

20 Oct 2011

OncoSec submits Device Master File for OMS to FDA

OncoSec Medical Incorporated, which is developing its advanced-stage OMS ElectroOncology therapies for the treatment of solid tumor cancers, announced today the submission of its Device Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its patented OncoSec Medical System (OMS) which consists of a generator and hand-held applicator.

20 Oct 2011

New surgical tool can identify tumor margins during brain operation

Scientists are reporting development and successful initial testing of a new tool that tells whether brain tissue is normal or cancerous while an operation is underway, so that surgeons can remove more of the tumor without removing healthy tissue, improving patients' survival.

20 Oct 2011

Advances in yttrium-90 radioembolization for liver cancer

Finding innovative, minimally invasive ways to treat liver cancer-and being able to tailor that treatment individually to patients-are hallmarks of interventional radiologists. Advances in yttrium-90 (Y-90) radioembolization for liver cancer, a leading cause of cancer deaths worldwide, are reported in studies in the October Journal of Vascular and Interventional Radiology.

20 Oct 2011

'Lance Armstrong effect' could become powerful new cancer weapon

The "Lance Armstrong effect" could become a powerful new weapon to fight cancer cells that develop resistance to chemotherapy, radiation and other treatments, scientists say in a report in the ACS journal Molecular Pharmaceutics.

20 Oct 2011

Comprehensive roadmap promises to improve cancer immunotherapy development

The Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute (CRI) and the Association for Cancer Immunotherapy (CIMT) have issued a joint white paper, published in the October 13 issue of Nature Biotechnology, outlining a comprehensive roadmap that promises to help improve and facilitate the path forward in the development of novel immunotherapies for cancer.

19 Oct 2011